DISCLAIMER: THIS PAGE IS INTENDED FOR HEALTHCARE PROFESSIONALS AND OTHER RELEVANT DECISION MAKERS IN Canada ONLY.
Information about the NuvaxovidTM COVID-19 Vaccine (Recombinant protein, Adjuvanted) (also known as NVX-CoV2373)
NuvaxovidTM COVID-19 Vaccine (Recombinant protein, Adjuvanted) is indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 12 years of age and older and as a homologous booster given approximately 6 months after completion of the second dose of the primary series in individuals 18 years of age and older.
Drug Identification Number (DIN): 02525364
Report an Adverse Event (AE)
If you are concerned about an adverse reaction, it should be reported to Health Canada by:
- Visiting the web page on adverse reaction reporting (https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.
Product Quality Complaint
If you would like to report a complaint regarding the quality of a product, you can access the Health Canada product complaint form via this link: www.healthycanadians.gc.ca/apps/radar/MD-IM-0005.08.html
09:00 - 17:00
Monday - Friday